Post-­‐Doc position-2, DeAR Lab R. Mallone & S. You

The Postdoc will work on a project entitled “Resetting self-tolerance in autoimmune diabetes by proresolving mediators derived from apoptotic cell efferocytosis”. Type 1 diabetes (T1D) is a chronic autoimmune disease resulting from the selective destruction of insulin-secreting pancreatic β-cells by autoreactive T lymphocytes. We hypothesize that administration of pro-resolving mediators, issued from apoptotic cell phagocytosis by macrophages (called efferocytosis), may constitute a promising strategy for controlling the dysregulated immune responses characteristic of T1D. Our research program will use both the non-obese diabetic (NOD) mouse model and samples from T1D patients. Our first objective is to assess the capacity of NOD macrophages to produce pro-resolving mediators after apoptotic cell efferocytosis. A strong focus will be brought on immunomodulatory cytokines and lipid subclasses
(lipidomic approach). The second objective is to evaluate the therapeutic effect of the pro-resolving mediators in autoimmune diabetes (NOD mouse model). Third, production of human pro-resolutive factors from T1D and healthy subjects will be compared to identify biomarkers of T1D.

Find out more

Post-­‐Doc position-1, DeAR Lab R. Mallone & S. You

The Postdoc will work on a project entitled “Identifying T-cell responses against viral epitopes and their potential cross-reactivity with islet autoantigens”. T lymphocytes are key effectors in the autoimmune destruction of insulin-producing pancreatic beta cells. Environmental factors play a dominant role over genetic predisposition, yet these factors remain elusive. We will be examining the potential role of viral infections and mechanisms thereof, with a particular focus on the cytotoxic effects directly exerted on beta cells and/or on triggering of autoimmune T cells through viral amino acid sequences sharing homology with beta-cell epitopes. The ultimate goal is to establish whether a causal relationship between viral infections and beta-cell autoimmunity may exist, and to gain information to guide the development of
preventative vaccines.

Find out more

Postdoc or PhD student in Netherland

Your function within the department

You will become part of an international team doing basic and translational research aimed to improve cancer immunotherapy. In our group, we aim to understand the requirements for initiation of a tumor-specific T cell response at the molecular level, and explore the concept of immunogenic cell death. Your project is carried out in vivo in mouse models and matching cellular systems in vitro. This project is part of a translational research line in which we collaborate with the divisions of radiotherapy, medical oncology and surgery.

Find out more

ESR-Early Stage Researcher (PhD student)

One position as ESR-Early Stage Researcher (PhD student) in the field of Immunotherapy of Cancer.

Description: IMMUTRAIN is a research network funded by the Marie Skłodowska-Curie Actions. It comprises nine academic research groups and five industrial partners in nine European countries. The joint goal is to train the next generation of scientists in the field of immunotherapy of cancer. The research objective of IMMUTRAIN is to enhance the efficacy of antibody-based tumor therapies through combination with other immunotherapeutic approaches. Please find further information at

Find out more

Postdoc posistion in Immunology Aarhus

Postdoc position in Immunology at the Department of Biomedicine, Aarhus University, Denmark
A fully funded 2-year postdoctoral position is available from November 2017, or as soon as possible thereafter, in The Laboratory for Lymphocyte Biology, Department of Biomedicine, Aarhus University, Denmark.
We seek a highly motivated postdoctoral candidate to study maternofetal immune influences in autoimmune mouse models, with a focus on downstream neurodevelopmental consequences.

Find out more

Postdoctoral scientist in cancer immunotherapy (PhD, MD, pharmacist, veterinarian or equivalent) (male/female)

Scope of the project:
We are offering an exciting scientific position in the field of tumor immunology in a highly clinically relevant research area. The focus of the group Immunopharmacology (Head: PD Dr. Sebastian Kobold) is the development of new anti-tumoral immunotherapies. The project will focus on the development of a novel strategy for cellular therapy of cancer. All projects are embedded in the doctorate program i-Target (Immunotargeting of Cancer) of the Elite Network of Bavaria ( and the Marie-Sklodowska Curie Network IMMUTRAIN, funded by the European Union.

Application deadline: 31st of July 2017

Find out more

Professor in Innate Immunology

The Department og Molecular Biology and Genetics wishes to strengthen its research expertise and activities in Innate Immunology with the focus on molecular cell biology of immunology in support of a strategic focus area in Molecular Medicine (please see the strategy of the department). The candidate is expected to play a central role in recruiting and supervising pre- and post-doctoral fellows as well as in teaching courses in immunology at both the undergraduate and graduate levels. The position is open from October 1st 2017.

All applications must be made online and received by: 15.06.2017

Find out more

Professor in nutritional immunology

We are looking for a new professor in nutritional immunology here at Århus University, Denmark.

Information about the position and how to apply online can be found in this link:

Application deadline is 22/6-2017

Tina Sørensen Dalgaard, MSc, PhD
Dept. of Animal Science
Immunology and Microbiology unit
Aarhus University
Blichers Allé 20, P.O. box 50
8830 Tjele, Denmark

Direct Tel.: +45 87158052

10 PhD positions within tumor treatment

The European Network on Anti-Cancer Immuno-Therapy Improvement by modification of CAR and TCR Interactions and Nanoscale Geometry (EN-ACTI2NG), formed by 12 academic, clinical and industrial institutions from Spain, Austria, Germany, The Netherlands and the United Kingdom offers a multidisciplinary training for 10 early stage researchers in the development and analysis of engineered tumor-specific immune receptors. This network, funded by the H2020 Marie Sklodowska Curie Action program, emanates from recent clinical evidence that T cells expressing engineered tumor-specific immune receptors can eradicate tumors that do not respond to conventional treatment. This important therapeutic approach is in a very early phase of development and requires a well-trained workforce to address challenges such as development of tumor-specific receptors for a wider array of tumors, improvement in efficiency of these receptors, better on/off-target toxicity safety profiles and more efficient transfer of basic research findings to the clinic.

Application not later than May 1st 2017

Find out more